Rao S, Tsang L, Zhao M, Shi W, Lu Q
Front Med (Lausanne). 2022; 9:881431.
PMID: 36072947
PMC: 9442343.
DOI: 10.3389/fmed.2022.881431.
Colafrancesco S, Manara M, Bortoluzzi A, Serban T, Bianchi G, Cantarini L
Arthritis Res Ther. 2019; 21(1):275.
PMID: 31829244
PMC: 6907145.
DOI: 10.1186/s13075-019-2021-9.
Parisi F, Paglionico A, Varriano V, Ferraccioli G, Gremese E
Medicine (Baltimore). 2017; 96(24):e6656.
PMID: 28614216
PMC: 5478301.
DOI: 10.1097/MD.0000000000006656.
Agnihotri A, Ruff A, Gotterer L, Walker A, McKenney A, Brateanu A
Case Rep Med. 2016; 2016:2071815.
PMID: 27847518
PMC: 5101375.
DOI: 10.1155/2016/2071815.
Gopalarathinam R, Orlowsky E, Kesavalu R, Yelaminchili S
Case Rep Rheumatol. 2016; 2016:6502373.
PMID: 27042373
PMC: 4794578.
DOI: 10.1155/2016/6502373.
Interleukin-1 function and role in rheumatic disease.
Schett G, Dayer J, Manger B
Nat Rev Rheumatol. 2015; 12(1):14-24.
PMID: 26656658
DOI: 10.1038/nrrheum.2016.166.
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.
Lopalco G, Cantarini L, Vitale A, Iannone F, Anelli M, Andreozzi L
Mediators Inflamm. 2015; 2015:194864.
PMID: 25784780
PMC: 4345261.
DOI: 10.1155/2015/194864.
Treatment of adult-onset Still's disease: a review.
Jamilloux Y, Gerfaud-Valentin M, Henry T, Seve P
Ther Clin Risk Manag. 2015; 11:33-43.
PMID: 25653531
PMC: 4278737.
DOI: 10.2147/TCRM.S64951.
An expanding role for interleukin-1 blockade from gout to cancer.
Dinarello C
Mol Med. 2014; 20 Suppl 1:S43-58.
PMID: 25549233
PMC: 4374514.
DOI: 10.2119/molmed.2014.00232.
Treating inflammation by blocking interleukin-1 in humans.
Dinarello C, van der Meer J
Semin Immunol. 2013; 25(6):469-84.
PMID: 24275598
PMC: 3953875.
DOI: 10.1016/j.smim.2013.10.008.
Adult-onset Still's disease revealed by perimyocarditis and a concomitant reactivation of an EBV infection.
Meckenstock R, Therby A, Gibault-Genty G, Khau D, Monnier S, Greder-Belan A
BMJ Case Rep. 2012; 2012.
PMID: 23166163
PMC: 4545114.
DOI: 10.1136/bcr.01.2011.3688.
Anti-Interleukin-1 Agents in Adult Onset Still's Disease.
Giampietro C, Fautrel B
Int J Inflam. 2012; 2012:317820.
PMID: 22611515
PMC: 3350963.
DOI: 10.1155/2012/317820.
Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.
Goldbach-Mansky R
Clin Exp Immunol. 2012; 167(3):391-404.
PMID: 22288582
PMC: 3374271.
DOI: 10.1111/j.1365-2249.2011.04533.x.
Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study.
Laskari K, Tzioufas A, Moutsopoulos H
Arthritis Res Ther. 2011; 13(3):R91.
PMID: 21682863
PMC: 3218906.
DOI: 10.1186/ar3366.
Autoinflammation: translating mechanism to therapy.
Doherty T, Brydges S, Hoffman H
J Leukoc Biol. 2011; 90(1):37-47.
PMID: 21330349
PMC: 3219035.
DOI: 10.1189/jlb.1110616.
[IL-1 antagonists].
Kotter I, Horneff G
Z Rheumatol. 2010; 69(7):581-93.
PMID: 20703489
DOI: 10.1007/s00393-009-0530-7.
Blocking interleukin-1 in rheumatic diseases.
Goldbach-Mansky R
Ann N Y Acad Sci. 2010; 1182:111-23.
PMID: 20074280
PMC: 3080043.
DOI: 10.1111/j.1749-6632.2009.05159.x.
Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses.
Goldbach-Mansky R, Kastner D
J Allergy Clin Immunol. 2009; 124(6):1141-9.
PMID: 20004775
PMC: 2995268.
DOI: 10.1016/j.jaci.2009.11.016.
Therapy of autoinflammatory syndromes.
Hoffman H
J Allergy Clin Immunol. 2009; 124(6):1129-38.
PMID: 20004774
PMC: 4508191.
DOI: 10.1016/j.jaci.2009.11.001.
[Recommendations on therapy using interleukin-1beta-blocking agents].
Manger B, Gaubitz M, Michels H
Z Rheumatol. 2009; 68(9):766-71.
PMID: 19756659
DOI: 10.1007/s00393-009-0542-3.
